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Summary
Introduction. — Heart failure (HF) is associated with high morbidity and mortality. A significant
component of HF-related adverse outcome occurs during hospitalization.
Objective. — To assess features and in-hospital outcomes of patients hospitalized for a first
episode of HF.
Methods. — We prospectively recruited 799 consecutive patients hospitalized for a first episode
of HF during 2000 in the Somme department (France). We evaluated in-hospital mortality in
this cohort, identified factors predictive for hospital death, and compared the mortality in
patients with preserved or reduced ejection fraction (EF).
Results. — The mean age of the study population was 75±12 years. EF, assessed in 662
patients (83%), was preserved (≥50%) in 56% of cases. During hospitalization, 64 deaths (8%)
were recorded. The major causes of in-hospital death were acute pulmonary oedema (50%)
and cardiogenic shock (22%). Coronary artery disease, low systolic blood pressure on
admission, increased heart rate on admission, renal failure, reduced EF (<50%) and older age
were identified as independent predictors of in-hospital mortality. Patients with preserved
EF were older and comprised a greater proportion of women. In-hospital mortality of the
reduced EF group was higher than that of the preserved EF group (8.2% versus 2.7%,
p=0.002). On multivariable analysis, reduced EF was independently associated with in-
hospital death (odds ratio 2.32; 95% confidence interval 1.06-5.11; p=0.03). In propensity-
matched patients, in-hospital mortality was higher in the reduced EF group (7.6% versus 2.2%
p=0.02). 
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Conclusion. — The in-hospital outcome of patients admitted for new-onset HF is poor. Patients
with preserved EF are older but have lower in-hospital mortality.
© 2008 Published by Elsevier Masson SAS.
Résumé 
Introduction. — L’insuffisance cardiaque (IC) est associée à une importante morbidité et
mortalité. Peu de données sur la mortalité en phase hospitalière lors d’une première poussée
d’IC sont disponibles.
Objectif. — Déterminer les caractéristiques et la mortalité hospitalière des patients admis pour
une première poussée d’IC dans le département de la Somme.
Méthodes. — 799 patients consécutifs hospitalisés pour une première poussée d’IC pendant
l’année 2000 dans le département de la Somme (France) ont été prospectivement inclus. Dans
cette cohorte, on a évalué la mortalité hospitalière, identifié les facteurs prédictifs de
mortalité et comparé la mortalité des insuffisants cardiaques à fraction d’éjection (FE)
préservée et altérée.
Résultats. — L’âge moyen de la population était de 75 ± 12 ans. La FE, évaluée chez 662 patients
(83 %) était préservée (≥ 50 %) dans 56 % des cas. Pendant l’hospitalisation, ont été enregistrés
64 décès (8 %). Les causes principales de mortalité hospitalière étaient l’œdème pulmonaire aigu
(50 %) et le choc cardiogénique (22 %). La présence d’une maladie coronaire, la tension artérielle
basse à l’entrée, la fréquence cardiaque augmentée à l’entrée, l’insuffisance rénale, la FE
altérée (FE < 50 %) et l’âge ont été identifiés comme facteurs prédictifs indépendants de
mortalité hospitalière. Les patients à FE préservée étaient plus âgés et en majorité de sexe
féminin. La mortalité hospitalière du groupe à FE altérée était plus importante par rapport au
groupe à FE préservée (8,2 % versus 2,7 %, p = 0,002). En analyse multivariée, la FE altérée était
associée à la mortalité hospitalière (odds ratio 2,32 ; 95 % intervalle de confidence 1,06-5,11 ;
p = 0,03). Après appariement (« propensity analysis »), la mortalité hospitalière demeurait plus
grande pour les patients à FE altérée (7,6 % versus 2,2 %, p = 0,02).
Conclusion. — Pendant la phase hospitalière, l’évolution des patients admis pour une première
poussée d’IC est réservée. Les patients à FE préservée sont plus âgés mais ont une mortalité
hospitalière plus bas.
© 2008 Published by Elsevier Masson SAS.
Introduction
Heart failure (HF) represents a major cause of morbidity and
mortality in western countries. In the United States, approxi-
mately 5 million people have HF and 550,000 each year are
newly diagnosed with the condition [1]. Patients with HF
experience nearly 1,100,000 annual hospitalizations for HF
[2]. In-hospital mortality represents an understudied compo-
nent of HF-related adverse outcomes. Reported mortality
rates during hospitalization vary widely depending on popula-
tion profile and HF diagnostic criteria [3-12]. In the EuroHeart
Failure Survey programme, which included patients from
24 countries in Europe, in-hospital mortality rates ranged
from 1.3% to 10.2% [3]. Moreover, heart failure with preser-
ved ejection fraction (HFPEF) is an increasingly prevalent
form, responsible for approximately 50% of all admissions for
decompensated HF [3-5, 13]. Scarce data are available on in-
hospital outcome of patients with HFPEF [14].
The objectives of this hospital-based observational
study, which prospectively included patients admitted for a
first episode of HF in all establishments managing HF
patients in a single French department, were: 1) to des-
cribe the clinical characteristics of patients admitted to
hospital with a new diagnosis of HF, 2) to assess the in-hos-
pital mortality in this cohort and to identify independent
predictive factors of adverse in-hospital outcome, and 3) to
compare the in-hospital mortality of patients with HFPEF
with that of patients with HF and reduced left ventricular
(LV) ejection fraction (EF).
Methods
Population and inclusion criteria
Somme is a fairly rural department in the north of France
with a population of 555,551 inhabitants according to the
1999 census. There are 11 healthcare establishments mana-
ging patients with HF: 1 university hospital, 7 general hos-
Abbreviations
ACE Angiotensin-converting enzyme
EF Ejection fraction
HF Heart failure
HFPEF Heart failure with preserved ejection frac-
tion
HR Heart rate
LV Left ventricular
NYHA New York Heart Association
SBP Systolic blood pressure
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pitals, 2 private clinics and 1 medium and long-stay unit.
General practitioners, cardiologists and internal physicians
in these centres agreed to participate in this study.
Consecutive patients older than 20 years, hospitalized
for a first episode of HF in any of these centres during 2000
were enrolled prospectively. Patients living outside
Somme, patients hospitalized for subsequent episodes of
HF, and patients with severe valvular disease requiring sur-
gery were excluded. We also excluded patients hospitalized
primarily for acute myocardial infarction. The diagnosis of
HF was made by the attending physician in 811 patients,
based on history, symptoms, physical signs and chest X-ray
on admission. Two cardiologists, specifically recruited for
this purpose, reviewed during the index hospitalization all
medical records in order to validate the diagnosis of HF
according to the Framingham criteria amended by the Euro-
pean Society of Cardiology [15]. The diagnosis was valida-
ted in 799 patients (410 men and 389 women) who comprise
the study population.
Data collection
Clinical data including medical history, cardiovascular risk
factors, and results of complementary investigations (labo-
ratory tests, electrocardiogram, chest X-ray on admission,
echocardiography, and in some patients, coronary angio-
graphy) were recorded on individual case-report forms. EF
was determined during the index hospitalization in
662 patients (83%) by echocardiography (n=648) and/or left
ventriculography (n=103). Echocardiograms were recorded
according to the guidelines of the American Society of
Echocardiography [16]. When more than one method was
performed, an average EF was calculated. A cut-off of 50%
was used to distinguish HFPEF from HF with reduced EF [17-
20]. An estimate of glomerular filtration rate on admission
was calculated using the simplified Modification of Diet in
Renal Disease formula [21]. In-hospital mortality rates were
determined. Causes of death were ascertained from hospi-
tal records and autopsy records. 
Statistical analysis
Continuous variables are expressed as mean±standard
deviation and were compared using Student’s t-test. Cate-
gorical variables are summarized by frequency percents
and were analysed by the χ2 test or Fisher’s exact test, as
appropriate. Univariate analyses tested all baseline charac-
teristics that potentially could be associated with in-hospi-
tal mortality. For multivariable analyses, we used a logistic
regression model that included variables considered of
potential prognostic importance (age, sex, history of hyper-
tension, coronary artery disease, diabetes mellitus, chronic
obstructive pulmonary disease, stroke, cancer, systolic
blood pressure [SBP] on admission, heart rate [HR] on
admission, natraemia) and variables significantly associa-
ted with in-hospital death on univariate analysis. The
forward stepwise procedure (significance levels of 0.05 for
entry and 0.1 for removal) was applied to calculate odds
ratios and 95% confidence intervals for the set of variables
independently associated with an adverse in-hospital out-
come. A separate logistic regression model was run in patients
in whom EF data were available.
The significant imbalance in baseline variables between
patients with preserved or reduced EF was lowered using
propensity scores. We estimated the propensity scores for
each of the 294 patients with reduced EF using a multivaria-
ble logistic model, as previously described [22,23]. Charac-
teristics associated with the presence of reduced EF on uni-
variate analysis (p≤0.15) were included in the multivariable
logistic model in a forward stepwise regression analysis.
Using the resulting selected variables, a propensity score
for each patient was estimated by maximum likelihood
regression analysis. The propensity scores were used to
match each patient with reduced EF to a unique patient
with preserved EF with a propensity score within 2%. First
we matched each patient with reduced EF with another in
the preserved EF group that had the same 5-digit propensity
score and removed the matched patients from the data-
base. The procedure was repeated in the remaining
patients with successive matching by 4-, 3-, and 2-digit sco-
res. One-hundred and eighty five (63%) of the 294 patients
with reduced EF were successfully matched. The mean pro-
pensity score in patients with reduced EF before matching
was 0.56649 compared to 0.34345 in those with preserved
EF (p<0.001). In the group that resulted after matching, the
mean propensity score was 0.47425 in patients with redu-
ced EF, comparable to that of the preserved EF group
(0.47502; p=0.97). Baseline characteristics of the groups
resulting after matching were compared using Student’s t
test and the χ2 test, as appropriate. Goodness-of-fit (Hos-
mer-Lemeshow test) and discriminatory power (area under
the receiver-operating characteristic curve, C) were
assessed for all multivariable logistic models. For all tests,
a p-value (two-sided) ≤0.05 was considered statistically
significant. Statistical analysis was performed with SPSS
13.0 statistical software (SPSS Inc., Chicago, IL, USA).
The study complies with the Declaration of Helsinki and
was approved by local institutional review boards. Informed
consent was obtained from all patients. The database was
approved by the French computers and privacy commission.
Results
Features of the study population
The study population comprised 799 patients (410 men and
389 women). The sex ratio was 1.05. The mean age was
75±12 (range 25–100) years, with a mean age of 73±12 years
in men and 78±11 years in women (p<0.001); 77% of
patients were older than 70 years and 38% were older than
80 years. Most patients were hospitalized in cardiology
units (n=607, 76%), 13% (n=106) in internal medicine
departments, and 11% (=85) in geriatric units. The mean
hospital stay was 10.8±7.0 days and 210 patients (26%) had
a stay in intensive care units during hospitalization. 
The baseline characteristics of the study population are
displayed in table 1. The most frequent risk factors were
hypertension (62%) and smoking (35%). Twenty-five per
cent of patients were diabetic. Coronary artery disease was
identified in 38% of patients (n=302) and valvular disease in
9% (n=72). Non-cardiac comorbidities were frequently
observed. Thirty three per cent of patients had atrial
fibrillation on baseline ECG.
Ejection fraction was assessed in 662 patients (83%). EF
was preserved (≥50%) in 56% of cases (n=368). Characteris-
tics of patients according to EF are presented in tables 2
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and 3. Mean hospital stay was similar for patients with
reduced or preserved EF (10.6±6.7 versus 10.4±6.6 days,
p=0.84). Compared to patients with preserved EF, a greater
proportion of those with reduced EF had a stay in intensive
care units (24% versus 34%, p=0.005). Patients with preser-
ved EF were significantly older and comprised a greater
proportion of women. Patients with HFPEF had more often
a history of hypertension, a greater frequency of valvular
disease, and less frequently had coronary artery disease or
prior myocardial infarction. Peripheral artery disease was
more frequent in patients with reduced EF (table 3).
In-hospital outcome
The in-hospital mortality was 8% (64 deaths). The main
cause was acute pulmonary oedema (50%) followed by car-
diogenic shock (22%). In patients older than 75 years, the
in-hospital mortality rate was 10.6% (51 deaths).
On univariate analysis, patients who died during the
index hospitalization were older, had a significantly lower
SBP on admission, a higher HR on admission, and more often
had coronary artery disease and renal failure. History of
hypertension and atrial fibrillation on admission appeared
to be related to better outcome. EF was significantly lower
in patients who died during hospitalization (table 2). By
multivariable logistic regression, the following independent
predictors of in-hospital mortality were identified in the
overall study population: coronary artery disease
(p<0.001), SBP on admission ≤100 mmHg (p=0.004), older
age (p=0.001), and HR on admission >100 bpm (p=0.002;
table 4). In patients in whom EF was assessed, coronary
artery disease, SBP on admission ≤100mm Hg, estimated
Table 1 Baseline characteristics and predictors of in-hospital mortality in the overall study population (n=799).
Variable All (n=799) Alive (n=735) In-hospital death (n=64) p
Demographic data and initial vital signs
Age (years)
Women
Smoker
NYHA class III–IV on admission
SBP on admission (mmHg)
HR on admission (bpm)
SBP on admission ≤100 mmHg
HR on admission >100 bpm
Cardiac history
Coronary artery disease
Myocardial infarction
Hypertension
Valvular heart disease
Atrial fibrillation at baseline
Left bundle branch block
Non-cardiac comorbidities
Diabetes mellitus
Stroke
Peripheral artery disease
Chronic obstructive pulmonary disease
Cancer
75.4±11.9
48.7% (389)
35.4% (283)
95.4% (762)
148.5±31.2
94.8±26.1
6% (48)
39.2% (313)
37.8% (302)
12.8% (102)
62.3% (498)
9.0% (72)
33.0% (264)
13.6% (109)
24.5% (196)
5.6% (45)
13.8% (110)
19.5% (156)
10.7% (85)
74.5±11.9
48.4% (356)
35.6% (262)
95.1% (699)
149.7±30.7
94.5±26.5
5.2% (38)
38% (278)
35.4% (260)
12.7% (93)
63.0% (463)
9.5% (70)
33.7% (248)
13.6% (100)
24.6% (181)
5.4% (40)
14.3% (105)
19.9% (146)
10.3% (75)
80.3±11.2
51.6% (33)
32.8% (21)
98.4% (63)
133.7±32.7
98.2±19.7
15.9% (10)
55.6% (35)
65.6% (42)
14.1% (9)
54.7% (35)
3.1% (2)
25.0% (16)
14.1% (9)
23.4% (15)
7.8% (5)
7.8% (5)
15.6% (10)
15.6% (10)
0.001
0.63
0.65
0.22
<0.001
0.16
0.001
0.006
<0.001
0.75
0.19
0.08
0.15
0.92
0.83
0.43
0.16
0.41
0.18
Laboratory data on admission
Sodium (mEq/L)
Glomerular filtration rate (mL/min/1.73m2)
137.3±4.7
58.5±23.8
137.4±4.5
59.3±23.5
136.5±6.1
49.1±25.3
0.25
0.001
Baseline medical therapy
Angiotensin-converting enzyme inhibitor
Beta-blocker
Loop diuretic
Aldosterone antagonist
Digoxin
Calcium channel blocker
Nitrate
Angiotensin-receptor blocker
Amiodarone
Oral anticoagulant
Platelet aggregation inhibitor
16.5% (131)
16.2% (129)
24.8% (198)
8.4% (67)
7.4% (59)
15.5% (123)
15.5% (123)
4.8% (38)
8.2% (65)
8.4% (67)
20.5% (163)
16.9% (124)
16.2% (119)
25.3% (186)
8.3% (61)
7.4% (54)
15.8% (116)
15.5% (114)
4.8% (35)
8.6% (63)
8.6% (63)
20.0% (147)
11.5% (7)
15.6% (10)
19.7% (12)
9.8% (6)
8.2% (5)
11.5% (7)
14.8% (9)
4.9% (3)
3.3% (2)
6.6% (4)
26.2% (16)
0.27
0.90
0.33
0.68
0.81
0.37
0.87
0.96
0.17
0.58
0.25
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glomerular filtration rate ≤60 mL/min/1.73m2 and reduced
EF (<50%) were independently associated with higher in-
hospital mortality (table 4).
In-hospital outcome according 
to left ventricular ejection fraction
The in-hospital mortality of the reduced EF group was 8.2%
(24 deaths), significantly higher than that of the preserved
EF group (10 deaths, 2.7%, p=0.002). In the reduced EF
group, all deaths were due to cardiovascular causes. The
two main causes were acute pulmonary oedema (50% of
deaths, n=12) and cardiogenic shock (37.5% of cases, n=9),
followed by sudden death (8.4% of cases, n=2) and stroke
(4.2% of cases, n=1). In patients with preserved EF, 90% of
deaths were cardiovascular. Acute pulmonary oedema was
the cause of death in 40% of cases (n=4), sudden death in
30% (n=3), and cardiogenic shock in 10% (n=1). One patient
died of cerebral haemorrhage (10%) and one of acute pan-
creatitis (10%).
In-hospital death rates of HFPEF patients of ischaemic,
hypertensive, and valvular aetiology were not significantly
different (3.9%, 2.6% and 2.1%, respectively; overall p value
0.76).
Table 2 Baseline characteristics and predictors of in-hospital mortality in patients assessed for left ventricular ejection
fraction (n=662).
Variable All (n=662) Alive (n=628) In-hospital death (n=34) p
Demographic data and initial vital signs
Age (years)
Women
Smoker
NYHA class III–IV on admission
SBP on admission (mmHg)
HR on admission (bpm)
SBP on admission ≤100 mmHg
HR on admission >100 bpm
Cardiac history
Coronary artery disease
Myocardial infarction
Hypertension
Valvular heart disease
Atrial fibrillation at baseline
Left bundle branch block
Non-cardiac comorbidities
Diabetes mellitus
Stroke
Peripheral artery disease
Chronic obstructive pulmonary disease
Cancer
73.7±11.8
46.2% (306)
38.4% (254)
95.2% (630)
148.1±31.0
94.5±26.7
5.7% (38)
39.3% (260)
37.3% (247)
12.8% (85)
62.2% (412)
10.7% (71)
33.5% (222)
13.6% (90)
25.8% (171)
5.1% (34)
15.0% (99)
20.5% (136)
10.3% (68)
73.5±11.7
46.7% (293)
38.1% (239)
95.1% (597)
148.9±30.5
94.4±26.9
5.1% (32)
39.3% (245)
35.5% (223)
12.6% (79)
62.7% (394)
11.0% (69)
34.4% (216)
13.7% (86)
25.8% (162)
4.9% (31)
15.1% (95)
20.7% (130)
10.4% (65)
76.5±12.9
38.2% (13)
44.1% (15)
97.1% (33)
130.1±32.9
97.2±22.5
18.2% (6)
45.5% (15)
70.6% (24)
17.6% (6)
52.9% (18)
5.9% (2)
17.6% (6)
11.8% (4)
26.5% (9)
8.8% (3)
11.8% (4)
17.6% (6)
8.8% (3)
0.15
0.34
0.48
0.60
0.001
0.56
0.002
0.48
<0.001
0.39
0.25
0.35
0.04
0.75
0.93
0.32
0.59
0.67
0.77
Left ventricular systolic function
Ejection fraction (%) 50.3±15.9 50.9±15.7 40.1±16.9 <0.001
Laboratory data on admission
Sodium (mEq/L)
Glomerular filtration rate (mL/min/1.73m2)
137.3±4.6
59.6±23.9
137.4±4.6
60.1±23.7
136.2±5.7
50.1±26.7
0.15
0.01
Baseline medical therapy
Angiotensin-converting enzyme inhibitor
Beta-blocker
Loop diuretic
Aldosterone antagonist
Digoxin
Calcium channel blocker
Nitrate
Angiotensin receptor blocker
Amiodarone
Oral anticoagulant
Platelet aggregation inhibitor
16.9% (111)
17.1% (113)
24.1% (159)
8.7% (57)
7.3% (48)
16.9% (111)
14.7% (97)
2.4% (16)
8.4% (55)
8.8% (58)
20.4% (134)
17.1% (107)
16.9% (106)
24.6% (154)
8.5% (53)
7.3% (46)
17.1% (107)
15.2% (95)
5.3% (33)
8.6% (54)
8.9% (56)
20.4% (128)
12.9% (4)
20.6% (7)
16.1% (5)
12.9% (4)
6.5% (2)
12.9% (4)
6.5% (2)
6.5% (2)
3.2% (1)
6.5% (2)
19.4% (6)
0.55
0.58
0.28
0.39
0.85
0.55
0.18
0.78
0.29
0.64
0.89
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After excluding from the HFPEF subset patients with a
previous myocardial infarction or with valvular disease, in
the remaining group (290 with HFPEF and 294 with reduced
EF), reduced EF (<50%) remained associated with higher in-
hospital death rates (8.2%, n=24 for the reduced EF group
versus 2.8%, n=8 for the preserved EF group; p=0.004).
By multivariable logistic regression analysis, propensity
scores were estimated for each of the 294 patients in the
reduced EF group. The goodness-of-fit (p=0.73) and discri-
minatory power of the model (C=0.77) were good. One-hun-
dred and eighty five patients with reduced EF were succes-
sfully matched. After this matching procedure, no
difference in baseline variables was observed between the
two groups (table 3). In propensity-matched patients, in-
hospital mortality was higher in the reduced EF group (7.6%
versus 2.2%, p=0.02). 
Discussion 
Current epidemiological data on HF are based on clinical
trials, hospital series, and several population studies, but
few studies have focused on patients hospitalized for a first
episode of HF [5,7,24-26]. In the present prospective, hos-
pital-based study we describe the clinical features and in-
hospital outcome of a cohort of patients admitted to hospi-
tal for new-onset HF. Our patients were enrolled from com-
Table 3 Baseline characteristics according to left ventricular ejection fraction before and after the matching procedure.
Variable Pre-match Post-match
EF≥50%
(n=368)
EF<50%
(n=294)
p EF≥50%
(n=185)
EF<50%
(n=185)
p
Demographics and initial vital signs
Age (years)
Women
Smoker
NYHA class III–IV on admission
SBP on admission (mmHg)
HR on admission (bpm)
SBP on admission ≤100 mmHg
HR on admission >100 bpm
Cardiac history
Coronary artery disease
Myocardial infarction
Hypertension
Valvular heart disease
Atrial fibrillation at baseline
Left bundle branch block
Non-cardiac comorbidities
Diabetes mellitus
Stroke
Peripheral artery disease
Chronic obstructive pulmonary disease
Cancer
Laboratory data on admission 
Sodium (mEq/L)
Glomerular filtration rate (mL/min/1.73m2)
Baseline medical therapy
Angiotensin-converting enzyme inhibitor
Beta-blocker
Loop diuretic
Aldosterone antagonist
Digoxin
Calcium channel blocker
Nitrate
Angiotensin receptor blocker
Amiodarone
Oral anticoagulant
Platelet aggregation inhibitor
75.8±10.0
53.0% (195)
32.6% (120)
95.4% (351)
153.2±31.2
90.9±27.1
4.1% (15)
33.2% (121)
28.0% (103)
9.2% (34)
73.6% (271)
13.0% (48)
35.9% (132)
8.4% (31)
26.1% (96)
4.9% (18)
11.4% (42)
20.4% (75)
12.0% (44)
137.5±4.5
59.4±23.8
20.7% (76)
22.8% (84)
29.6% (109)
10.9% (40)
8.4% (31)
18.2% (67)
17.7% (65)
7.4% (27)
9.5% (35)
10.1% (37)
22.0% (81)
71.0±13.4
38.0% (111)
45.6% (134)
95.2% (280)
141.6±29.5
99.0±25.5
7.9% (23)
47.6% (139)
49.0% (144)
17.3% (51)
48.0% (141)
7.8% (23)
30.6% (90)
20.1% (59)
25.5% (75)
5.4% (16)
19.4% (57)
20.7% (61)
8.2% (24)
137.1±4.9
59.9±24.1
12.1% (35)
9.9% (29)
17.2% (50)
5.9% (17)
5.9% (17)
15.2% (44)
11.0% (32)
2.8% (8)
6.9% (20)
7.2% (21)
18.3% (53)
<0.001
<0.001
0.001
0.93
<0.001
<0.001
0.04
<0.001
<0.001
0.002
<0.001
0.03
0.15
<0.001
0.87
0.75
0.004
0.91
0.11
0.30
0.81
0.004
<0.001
<0.001
0.02
0.21
0.30
0.02
0.009
0.23
0.21
0.24
74.1±10.7
47.8% (89)
37.6% (70)
94.1% (175)
145.0±30.4
98.4±26.3
6.5% (12)
45.9% (85)
36.0% (67)
14.0% (26)
59.7% (111)
12.9% (24)
33.9% (63)
14.0% (26)
25.8% (48)
3.2% (6)
16.1% (30)
24.2% (45)
14.1% (26)
137.1±4.6
58.2±20.9
16.7% (31)
10.2% (19)
21.0% (39)
10.2% (19)
4.3% (8)
17.2% (32)
16.7% (31)
8.1% (15)
9.7% (18)
8.6% (16)
20.4% (38)
73.4±12.3
45.2% (84)
38.2% (71)
96.8% (180)
145.5±31.1
96.2±25.4
7% (13)
41.1% (76)
41.9% (78)
14.0% (26)
56.5% (105)
8.6% (16)
34.4% (64)
13.4% (25)
23.1% (43)
4.3% (8)
15.1% (28)
19.9% (37)
9.2% (17)
137.3±4.5
57.7±22.4
13.3% (24)
12.4% (23)
19.9% (37)
5.9% (11)
7.0% (13)
16.7% (31)
12.9% (24)
4.3% (8)
9.1% (17)
8.6% (16)
20.4% (38)
0.56
0.60
0.92
0.22
0.88
0.43
0.84
0.35
0.24
1.00
0.53
0.18
0.91
0.88
0.55
0.59
0.78
0.32
0.15
0.65
0.81
0.29
0.51
0.80
0.13
0.26
0.89
0.31
0.13
0.86
1.00
1.00
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munity hospitals, private clinics, and a university hospital.
This design aimed to eliminate referral bias of hospital-
based studies conducted exclusively in tertiary centres that
usually include patients with more severe disease. The cli-
nical profile of our patients is similar to other contempo-
rary HF series with high proportions of elderly patients and
women and significant burden of non-cardiac comorbidities
[5, 7, 10-12]. The observed in-hospital mortality in the ove-
rall study population was 8%. Older age, coronary artery
disease, low SBP on admission, increased HR on admission,
renal failure, and reduced EF were identified as indepen-
dent predictors of in-hospital death. Using logistic regres-
sion and propensity scores we demonstrate that the in-hos-
pital mortality of patients with preserved EF is lower
compared with that of patients with reduced EF.
Characteristics of patients newly admitted 
to hospital for heart failure
The incidence of HF increases considerably with age [27].
The mean age of our cohort was 75 years, as in a recent hos-
pital-based study including patients admitted between
1993 and 2001 for new-onset HF [28]. In the Framingham
study, the mean age at the time of diagnosis of HF was
76 years [29]. In our study, the sex ratio was 1.05, close to
values reported by several authors [28,29], but lower than
other population-based studies [24,25]. The frequency of
coronary artery disease was probably underestimated in our
study as coronary angiography was not performed systema-
tically. Nevertheless, the frequency of coronary artery
disease (38%) in our study is similar to that reported in
other epidemiological studies of HF, such as the Leices-
tershire study [28]. Sixty two percent of our patients had
hypertension. This figure is lower than values reported in
the Framingham study, where 70% of men and 78% of
women had a history of hypertension [29]. In the Mayo Cli-
nic study, in 1999, 54% of patients were hypertensive [24].
During hospitalization, EF was assessed in 83% of
patients, an acceptable figure compared to frequencies
reported in recent studies, ranging between 42 and 84% [7,
18, 26, 30]. HFPEF was diagnosed in 56% of patients in
whom EF data were available. Recent data indicate that
HFPEF becomes the most frequent form of HF observed in
clinical practice [5, 13, 14]. Epidemiological studies have
shown that, as in our study, patients with HFPEF are older
and more often women, and that HFPEF is mainly due to
hypertension [1, 24, 30, 31].
In-hospital outcome and predictors of death
The prognosis of patients admitted to hospital for HF
remains poor [18]. Scarce data exist on the in-hospital out-
come of such patients [4-11, 14]. In our cohort, mortality
during hospitalization was 8%, a value identical to the in-
hospital mortality of patients with de novo acute HF inclu-
ded in the EuroHeart Failure Survey II [32]. However, as
reported in EuroHeart Failure Survey I, large variability in
hospital death rates associated with HF has been observed
in different participating European countries [3]. Hospital
death rates ranging between 7.1% and 23.4% have been
reported by several European population-based studies [6,
7, 28, 31, 33]. In-hospital fatality rates in American HF
populations are lower, ranging from 3.8% to 10% [8, 10-12,
34]. Differences in studied populations, healthcare provi-
ders and standards of care are possible explanations for
these findings. Stewart et al. have reported that short-term
outcomes following a first admission for HF exhibit signifi-
cant variation depending mainly on the type of hospital
managing the patients [6]. We tried to reduce this bias by
including in our cohort patients from all healthcare esta-
blishments in the Somme department, community hospi-
tals, private clinics, and a university hospital.
We identified several variables associated with an
increased risk of hospital death. Low SBP on admission and
coronary artery disease were the strongest predictors in our
cohort. Significant correlation between SBP on admission
and in-hospital outcomes has been reported in previous stu-
dies [8, 10, 12, 34]. Age over 75 years predicted in-hospital
death in the overall study population but not in patients
with an EF assessment during hospitalization. This was pro-
bably due to the fact that an EF assessment was not readily
available in very elderly patients hospitalized in geriatric
units and managed mostly by non-cardiologists. Renal
failure was an independent correlate of in-hospital morta-
lity, in agreement with data from the ADHERE (Acute
Decompensated Heart Failure National Registry) database
[12].
Table 4 Variables independently associated with in-hospital death — results of multivariable logistic regression.
Model Variable Odds ratio 95% confidence interval p value
Model 1*
(n=779)
Systolic blood pressure ≤100 mmHg
Coronary artery disease
Age ≥75 years
Heart rate >100 bpm
3.30
3.28
2.86
2.35
1.47–7.38
1.88–5.70
1.50–5.44
1.37–4.04
0.004
<0.001
0.001
0.002
Model 2†
(n=662)
Coronary artery disease
Systolic blood pressure ≤100 mmHg
Reduced ejection fraction (<50%)
Estimated glomerular filtration rate ≤60 mL/min/1.73m2
3.37
3.21
2.32
2.26
1.54–7.35
1.17–8.81
1.06–5.11
1.01–5.10
0.002
0.02
0.03
0.04
* Model 1 including age, sex, systolic blood pressure on admission, heart rate on admission, coronary artery disease, valvular disease, 
history of hypertension, diabetes mellitus, chronic obstructive pulmonary disease, cancer, stroke, atrial fibrillation, natremia, and esti-
mated glomerular filtration rate.
† Model 2 including variables included in model 1 and left ventricular ejection fraction.
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HFPEF has been extensively studied over the past 10
years. More than 50% of all cases of HF occur in the pre-
sence of a preserved EF (≥50%). The long-term prognosis of
patients hospitalized for HFPEF is poor. Previous studies
have reported that HFPEF patients have slightly lower mor-
tality rates compared to patients with reduced EF with
similar morbidity rates [18], whereas in our experience
patients hospitalized for a first episode of HF with preser-
ved or reduced EF had comparable 5-year survival rates
[13].
Some authors report comparable in-hospital death rates
in patients with preserved or reduced EF [7], while in other
studies patients with HFPEF experienced lower in-hospital
event rates [5, 14]. In the current study, although patients
with preserved EF were older, the in-hospital death rate of
the group with HFPEF was significantly lower than that of
the group with reduced EF. Logistic regression identified
reduced EF as independent predictor of in-hospital morta-
lity. To reduce the impact of baseline characteristics we
performed a propensity score analysis. After the matching
procedure using propensity scores, patients with reduced
EF still had higher in-hospital mortality. As expected, car-
diogenic shock was more frequent in patients with reduced
EF who died during hospitalization compared with patients
with preserved EF (37.5% versus 10%). This result is consis-
tent with French data from the EFICA (Epidémiologie Fran-
caise de l'Insuffisance Cardiaque Aiguë) study performed in
patients with acute HF, reporting that 18% of patients with
cardiogenic shock had preserved EF (>45%) [35].
Limitations
The diversity of the clinical signs of HF and their lack of
specificity can introduce an inclusion bias in epidemiologi-
cal studies related to an incorrect diagnosis. In our prospec-
tive study, the diagnosis of HF was made by the attending
physician and then confirmed using the Framingham crite-
ria, widely used in epidemiological surveys. In line with
recent recommendations, we adopted the cut-off value of
50% for HFPEF [17-20]. Echocardiography was not systema-
tically performed during the first hours after the patient’s
arrival as in all epidemiological studies of this type [24, 30].
Only 17% of patients were treated with beta-blockers on
admission, a percentage lower than the frequency of coro-
nary artery disease in our cohort. This represents a lack of
adherence to therapeutic guidelines in coronary artery
disease and shows that clinicians and general practitioners
were cautious in prescribing beta-blocker therapy in this
cohort of elderly patients with significant comorbidity
enrolled during 2000. More recent cohorts report a better
use of beta-blockers in HF patients with coronary artery
disease [32].
Since we did not assess diastolic parameters in this paper,
we have used the term “HFPEF” and not the term “diastolic
HF”. All HFPEF patients had clinical HF and EF ≥50%.
Although after myocardial infarction patients often develop
systolic LV dysfunction, a limited area of necrosis may result
in a preserved global LV systolic function, reflected by an EF
≥50%. Thus, 9% of patients with HFPEF in our cohort had a
previous myocardial infarction. The frequency of previous
myocardial infarction in patients with HFPEF in recent
published series varies between 16% and 24% [14, 26].
Conclusion
Patients admitted to hospital for a first episode of HF are
old, with a high frequency of hypertension and coronary
artery disease and significant comorbidities. The hospital
outcome of these patients is poor and can be predicted
using simple clinical data collected on admission. Important
differences exist between patients with HFPEF and those
with HF and reduced EF with regard to clinical characteris-
tics and in-hospital mortality.
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